Table 2.

GCA treatments at diagnosis and during follow-up.

	Without vascular event n = 215 n/available data (%)	With vascular event n = 39 n/available data (%)	p-value
Delay between diagnosis and onset of corticotherapy, days	11.8 ± 54.2 (0)	11.8 ± 23.6 (0)	>0.99
Initial dose/weight of prednisone, mg/kg per day)	0.8 ± 0.2 (0.7)	0.8 ± 0.2 (0.9)	0.36
Methylprednisolone infusion at diagnosis	35/213 (16.4%)	5/39 (12.8%)	0.81
Immunosuppressive drug at diagnosis	8/208 (3.8%)	0/38 (0.0%)	0.61
Platelet antiaggregant at diagnosis	121/209 (57.9%)	23/38 (60.5%)	0.85
Statin at diagnosis	40/208 (19.2%)	13/38 (34.2%)	0.05
Conversion enzyme inhibitor at diagnosis	23/201 (11.4%)	7/37 (18.9%)	0.27
Prednisone dose at month 3, mg/day	21.4 ± 10.8 (20)	25.3 ± 16.0 (20)	0.07
Prednisone dose at month 6, mg/day	11.0 ± 6.8 (10)	15.4 ± 12.6 (10)	0.06
Prednisone dose at month 12, mg/day	6.1 ± 5.5 (5)	6.6 ± 4.2 (6)	0.14
Prednisone dose at month 18, mg/day	4.3 ± 5.9 (5)	5.6 ± 4.1 (5)	0.02
Prednisone dose at month 24, mg/day	4.0 ± 6.9 (3)	4.8 ± 4.9 (5)	0.18
Prednisone dose >5 mg/day in the latest news	33/174 (19.0%)	4/30 (13.3%)	0.61
Prednisone dose = 0 mg/day in the latest news	77/173 (44.5%)	16/31 (51.6%)	0.55
Use of an immunosuppressive drug during follow-up	45/184 (24.5%)	9/34 (26.5%)	0.82
Delay between diagnosis and the use of an immunosuppressive drug, months	11.8 ± 14.1 (5)	22.6 ± 24.6 (12.5)	0.04

Data are expressed as mean ± σ (median) and number (percentage), n (%). Bold p value are <0.05.